Pharming Group (NASDAQ:PHAR) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Pharming Group (NASDAQ:PHAR) to a strong-buy rating in a report published on Saturday morning.

Several other equities analysts also recently commented on the stock. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Pharming Group in a research note on Monday, December 22nd. Zacks Research upgraded Pharming Group from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $38.00.

Pharming Group Stock Performance

NASDAQ:PHAR opened at $16.93 on Friday. The company has a debt-to-equity ratio of 0.35, a quick ratio of 2.39 and a current ratio of 3.16. Pharming Group has a fifty-two week low of $7.50 and a fifty-two week high of $18.30. The firm has a market cap of $1.16 billion and a PE ratio of -1,691.31. The business has a 50 day moving average price of $16.01 and a 200-day moving average price of $13.78.

Pharming Group (NASDAQ:PHAR) last issued its earnings results on Thursday, November 6th. The company reported $0.10 EPS for the quarter, topping the consensus estimate of $0.05 by $0.05. The company had revenue of $97.30 million for the quarter, compared to the consensus estimate of $98.22 million. Pharming Group had a net margin of 0.30% and a return on equity of 0.46%. Equities research analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

An institutional investor recently raised its position in Pharming Group stock. Silverberg Bernstein Capital Management LLC lifted its position in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) by 8.6% in the 2nd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 52,147 shares of the company’s stock after acquiring an additional 4,150 shares during the period. Silverberg Bernstein Capital Management LLC owned 0.08% of Pharming Group worth $557,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 0.03% of the company’s stock.

About Pharming Group

Pharming Group N.V. is a clinical-stage biopharmaceutical company headquartered in Leiden, the Netherlands, with a primary focus on developing and commercializing innovative protein replacement therapies for patients living with rare diseases. The company employs a proprietary transgenic technology platform designed to produce recombinant human proteins in the milk of transgenic animals, enabling scalable and cost-efficient manufacturing of complex therapeutic proteins.

The company’s lead product, RUCONEST (recombinant human C1 esterase inhibitor), is approved for the treatment of acute hereditary angioedema (HAE) attacks in multiple markets, including the United States and Europe.